130 related articles for article (PubMed ID: 26102249)
21. Combined Detection of HER2, Ki67, and GSTP1 Genes on the Diagnosis and Prognosis of Breast Cancer.
Song B; Wang L; Zhang Y; Li N; Dai H; Xu H; Cai H; Yan J
Cancer Biother Radiopharm; 2019 Mar; 34(2):85-90. PubMed ID: 30585764
[TBL] [Abstract][Full Text] [Related]
22. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
[TBL] [Abstract][Full Text] [Related]
23. Inverse relationship between Ki67 and survival in early luminal breast cancer: confirmation in a multivariate analysis.
Gallardo A; Garcia-Valdecasas B; Murata P; Teran R; Lopez L; Barnadas A; Lerma E
Breast Cancer Res Treat; 2018 Jan; 167(1):31-37. PubMed ID: 28865009
[TBL] [Abstract][Full Text] [Related]
24. Quantum-dot-based immunofluorescent imaging of HER2 and ER provides new insights into breast cancer heterogeneity.
Chen C; Peng J; Xia H; Wu Q; Zeng L; Xu H; Tang H; Zhang Z; Zhu X; Pang D; Li Y
Nanotechnology; 2010 Mar; 21(9):095101. PubMed ID: 20110584
[TBL] [Abstract][Full Text] [Related]
25. Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma.
Faratian D; Munro A; Twelves C; Bartlett JM
Histopathology; 2009 Jan; 54(2):254-7. PubMed ID: 19207951
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study.
Ma BB; Poon TC; To KF; Zee B; Mo FK; Chan CM; Ho S; Teo PM; Johnson PJ; Chan AT
Head Neck; 2003 Oct; 25(10):864-72. PubMed ID: 12966511
[TBL] [Abstract][Full Text] [Related]
27. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.
Bartlett JM; Munro A; Cameron DA; Thomas J; Prescott R; Twelves CJ
J Clin Oncol; 2008 Nov; 26(31):5027-35. PubMed ID: 18768436
[TBL] [Abstract][Full Text] [Related]
28. Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis.
Dieci MV; Barbieri E; Bettelli S; Piacentini F; Omarini C; Ficarra G; Balduzzi S; Dominici M; Conte P; Guarneri V
J Clin Pathol; 2012 Jun; 65(6):503-6. PubMed ID: 22389512
[TBL] [Abstract][Full Text] [Related]
29. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
30. The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer.
Pathmanathan N; Balleine RL; Jayasinghe UW; Bilinski KL; Provan PJ; Byth K; Bilous AM; Salisbury EL; Boyages J
J Clin Pathol; 2014 Mar; 67(3):222-8. PubMed ID: 24403187
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of molecular subtypes, ki67 expression and impact of postmastectomy radiation therapy in breast cancer patients with negative lymph nodes after mastectomy.
Selz J; Stevens D; Jouanneau L; Labib A; Le Scodan R
Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1123-32. PubMed ID: 22572073
[TBL] [Abstract][Full Text] [Related]
33. Histological grade as an alternative to the Ki67 labeling index is only available for luminal-type breast cancers.
Hayashi S; Kitada M; Sato K; Matsuda Y; Ishibashi K; Oikawa K; Miyokawa N; Hirata S
Breast Cancer; 2014 Jan; 21(1):47-51. PubMed ID: 22467403
[TBL] [Abstract][Full Text] [Related]
34. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
[TBL] [Abstract][Full Text] [Related]
35. CKAP2 (cytoskeleton-associated protein2) is a new prognostic marker in HER2-negative luminal type breast cancer.
Sim SH; Bae CD; Kwon Y; Hwang HL; Poojan S; Hong HI; Kim K; Kang SH; Kim HS; Um TH; Park IH; Lee KS; Jung SY; Lee S; Kang HS; Lee ES; Kim MK; Hong KM; Ro J
PLoS One; 2017; 12(8):e0182107. PubMed ID: 28771517
[TBL] [Abstract][Full Text] [Related]
36. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer.
Yamashita H; Nishio M; Toyama T; Sugiura H; Zhang Z; Kobayashi S; Iwase H
Breast Cancer Res; 2004; 6(1):R24-30. PubMed ID: 14680497
[TBL] [Abstract][Full Text] [Related]
37. The quantitative detection of total HER2 load by quantum dots and the identification of a new subtype of breast cancer with different 5-year prognosis.
Chen C; Xia HS; Gong YP; Peng J; Peng CW; Hu MB; Zhu XB; Pang DW; Sun SR; Li Y
Biomaterials; 2010 Nov; 31(33):8818-25. PubMed ID: 20723971
[TBL] [Abstract][Full Text] [Related]
38. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays.
Batistatou A; Televantou D; Bobos M; Eleftheraki AG; Kouvaras E; Chrisafi S; Koukoulis GK; Malamou-Mitsi V; Fountzilas G
Anticancer Res; 2013 May; 33(5):2139-45. PubMed ID: 23645767
[TBL] [Abstract][Full Text] [Related]
40. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer.
Criscitiello C; Disalvatore D; De Laurentiis M; Gelao L; Fumagalli L; Locatelli M; Bagnardi V; Rotmensz N; Esposito A; Minchella I; De Placido S; Santangelo M; Viale G; Goldhirsch A; Curigliano G
Breast; 2014 Feb; 23(1):69-75. PubMed ID: 24314620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
